Seven Fleet Capital Management LP Purchases New Position in Replimune Group, Inc. $REPL

Seven Fleet Capital Management LP purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the 1st quarter, HoldingsChannel.com reports. The fund purchased 120,400 shares of the company’s stock, valued at approximately $921,000.

Other hedge funds have also recently bought and sold shares of the company. Balyasny Asset Management L.P. boosted its holdings in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after acquiring an additional 2,195,448 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Replimune Group during the fourth quarter worth approximately $17,568,000. Commodore Capital LP acquired a new stake in Replimune Group during the 4th quarter worth approximately $13,851,000. EcoR1 Capital LLC acquired a new stake in Replimune Group during the 1st quarter worth approximately $7,650,000. Finally, JPMorgan Chase & Co. boosted its stake in Replimune Group by 2,333.6% in the 4th quarter. JPMorgan Chase & Co. now owns 925,173 shares of the company’s stock valued at $8,993,000 after purchasing an additional 887,157 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $11.20 on Friday. The firm has a 50 day moving average of $9.49 and a 200-day moving average of $7.38. The stock has a market capitalization of $941.14 million, a PE ratio of -3.31 and a beta of 0.86. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $12.50.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). On average, equities research analysts predict that Replimune Group, Inc. will post -2.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares in the company, valued at $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

REPL has been the topic of a number of research reports. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $9.00 to $12.00 in a report on Friday. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a report on Tuesday, June 30th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday. Jefferies Financial Group restated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Replimune Group currently has an average rating of “Hold” and an average price target of $9.29.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee backed results from the IGNYTE trial of RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma patients whose disease progressed after anti-PD-1 therapy. The panel considered the evidence and clinical benefit meaningful despite concerns about the trial design. Replimune surges after FDA advisers back skin cancer drug
• Positive Sentiment: The 10-3 vote was widely viewed as a favorable regulatory signal, with analysts describing the panel outcome as overwhelmingly positive and suggesting that RP1’s approval prospects have improved. REPL Stock Tracks Best Day Ever
• Positive Sentiment: Replimune formally announced the favorable committee outcome for its resubmitted Biologics License Application, giving investors a clearer path toward a potential commercial product. Replimune Announces Favorable Outcome of FDA Advisory Committee Meeting

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.